Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AnaptysBio, a therapeutic antibody product company, has received $860,482 in grants under the Qualifying Therapeutic Discovery Project program (QTDP).
Subscribe to our email newsletter
The funding has been awarded for four product programs, including the company’s differentiated anti-IL17 monoclonal antibody (mAb) program.
AnaptysBio said that the QTDP grant awards will help fund IND-enabling activities of a lead candidate in 2011 as well as support in advancing company’s other product programs.
The company uses somatic hypermutation (SHM) for antibody discovery and optimisation.
SHM is the body’s natural process for generating potent antibodies to fight disease. AnaptysBio’s SHM-XEL platform couples somatic hypermutation with mammalian cell display and flow cytometry to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection – a process that has been referred to as ‘naturalising’ antibodies.
The platform can be used for both discovery of new antibodies and optimisation of existing antibodies to generate candidates with desired binding and specificity properties for therapeutic applications
AnaptysBio chairman and CEO Tom Smart said that IL17 is a compelling target for the treatment of autoimmune and inflammatory diseases and has been validated by positive proof-of-concept results in recent clinical studies.
"Using the antibody discovery and optimisation capabilities of our SHM-XEL platform, we have generated multiple high-affinity anti-IL17 mAbs for this bio-superior program," Smart said.